Michael Badruddoja

3.4k total citations
20 papers, 681 citations indexed

About

Michael Badruddoja is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Michael Badruddoja has authored 20 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 9 papers in Oncology and 5 papers in Immunology. Recurrent topics in Michael Badruddoja's work include Glioma Diagnosis and Treatment (11 papers), Immunotherapy and Immune Responses (5 papers) and CAR-T cell therapy research (4 papers). Michael Badruddoja is often cited by papers focused on Glioma Diagnosis and Treatment (11 papers), Immunotherapy and Immune Responses (5 papers) and CAR-T cell therapy research (4 papers). Michael Badruddoja collaborates with scholars based in United States. Michael Badruddoja's co-authors include James J. Vredenburgh, David A. Reardon, Henry S. Friedman, James E. Herndon, Jennifer A. Quinn, Jeremy N. Rich, Allan H. Friedman, Jeannette M. Dowell, Annick Desjardins and Roger E. McLendon and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Michael Badruddoja

18 papers receiving 668 citations

Peers

Michael Badruddoja

GENET

ONCOL

PRM

Koji Oka Japan

Debra C. LaFrankie United States

Katharina Seystahl Switzerland

T. Mikkelsen United States

Wolfgang Wick Germany

Shannon Chang United States

L. Scopece Italy

Takanori Kamiryo Japan

Mario Caccese Italy

Kevin C. De Braganca United States

Koji Oka Japan

Michael Badruddoja

351 ×0.9

GENET

310 ×1.3

227 ×1.4

ONCOL

195 ×1.2

138 ×0.9

PRM

Citations per year, relative to Michael Badruddoja Michael Badruddoja (= 1×) peers Koji Oka

Countries citing papers authored by Michael Badruddoja

Since Specialization

Citations

This map shows the geographic impact of Michael Badruddoja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Badruddoja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Badruddoja more than expected).

Fields of papers citing papers by Michael Badruddoja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Badruddoja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Badruddoja. The network helps show where Michael Badruddoja may publish in the future.

Co-authorship network of co-authors of Michael Badruddoja

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Badruddoja. A scholar is included among the top collaborators of Michael Badruddoja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Badruddoja. Michael Badruddoja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peereboom, David M., Ross Lindsay, Michael Badruddoja, et al.. (2023). CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL. Neuro-Oncology. 25(Supplement_5). v61–v62. 2 indexed citations

Barkhoudarian, Garni, Michael Badruddoja, Sajeel Chowdhary, et al.. (2023). An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology. 12(3). CNS102–CNS102. 4 indexed citations

Peereboom, David M., Burt Nabors, Priya Kumthekar, et al.. (2018). Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. Journal of Clinical Oncology. 36(15_suppl). 2058–2058. 12 indexed citations

Peereboom, David M., Burt Nabors, Priya Kumthekar, et al.. (2018). Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). Annals of Oncology. 29. viii122–viii123. 7 indexed citations

Peereboom, David M., Burt Nabors, Priya Kumthekar, et al.. (2018). ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE. Neuro-Oncology. 20(suppl_6). vi2–vi2. 1 indexed citations

Badruddoja, Michael, Abhay Sanan, Kurt Schroeder, et al.. (2017). Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer Chemotherapy and Pharmacology. 80(4). 715–721. 23 indexed citations

Badruddoja, Michael, et al.. (2010). The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review. Letters in Drug Design & Discovery. 7(4). 290–299. 1 indexed citations

Badruddoja, Michael, Baldassarre Stea, M.C. Bishop, et al.. (2010). Phase II study of biweekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma multiforme.. Journal of Clinical Oncology. 28(15_suppl). e12554–e12554. 3 indexed citations

Badruddoja, Michael, Stephen T. Keir, Ivan King, et al.. (2007). Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro-Oncology. 9(3). 240–244. 5 indexed citations

10.

Badruddoja, Michael, Kara Penne, Annick Desjardins, et al.. (2006). Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme1. Neuro-Oncology. 9(1). 70–74. 11 indexed citations

11.

Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, et al.. (2005). Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 104(7). 1478–1486. 59 indexed citations

12.

Yu, John S., Keith L. Black, Gentao Liu, et al.. (2005). Results of a Phase II Trial of Tumor Lysate-pulsed Dendritic Cell Vaccination for Malignant Glioma. Neurosurgery. 57(2). 409–410.

13.

Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, et al.. (2005). Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology. 23(36). 9359–9368. 243 indexed citations

14.

Reardon, David A., Gamal Akabani, R. Edward Coleman, et al.. (2005). Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. Journal of Clinical Oncology. 24(1). 115–122. 150 indexed citations

15.

Das, Arabinda K., et al.. (2005). Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (Gbm). Journal of Clinical Oncology. 23(16_suppl). 1572–1572. 4 indexed citations

16.

Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, et al.. (2004). Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 103(2). 329–338. 97 indexed citations

17.

Badruddoja, Michael, et al.. (2004). Kluver-Bucy syndrome related to glioma. Neurology. 63(1). 184–184.

18.

Badruddoja, Michael, David A. Reardon, Gamal Akabani, et al.. (2004). Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. Journal of Clinical Oncology. 22(14_suppl). 1569–1569. 2 indexed citations

19.

Badruddoja, Michael, et al.. (2003). Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRIcerebral blood volume maps. Neuro-Oncology. 5(4). 235–243. 55 indexed citations

20.

Schmainda, Kathleen M., Scott D. Rand, Benjamin D. Ward, et al.. (2003). A Combined Gradient-Echo/Spin-Echo DSC Method: A Surrogate Marker for Brain Tumor Histologic Grade and Angiogenesis in Patients. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact